Page last updated: 2024-12-07

cholest-5-ene-3,4-diol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cholest-5-ene-3,4-diol: RN given refers to (3beta,4beta)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID86545
SCHEMBL ID1917363
MeSH IDM0261944

Synonyms (12)

Synonym
cholest-5-ene-3,4-diol
FT-0669464
FT-0669462
FT-0669463
10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-3,4-diol
SCHEMBL1917363
AKOS024419915
CZDKQKOAHAICSF-UHFFFAOYSA-N
cholest-5-ene-3.beta.,4.beta.-diol
(3s,4r,8s,10r,13r)-10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-3,4-diol
DTXSID40938338
PD044706

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The aim of the present study was to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of evogliptin in participants with renal impairment (RI)."( Effects of renal impairment on the pharmacokinetics and pharmacodynamics of a novel dipeptidyl peptidase-4 inhibitor, evogliptin (DA-1229).
Bahng, MY; Cho, H; Cho, JY; Jang, IJ; Kim, AH; Kim, YS; Lee, S; Oh, J; Yoon, SH; Yu, KS, 2017
)
0.46
" A simultaneous pharmacokinetic model of parent and active metabolites was initially developed by incorporating data from in vitro, preclinical, and clinical pharmacokinetic studies in healthy volunteers and in patients with AML or advSM."( Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin.
Chun, DY; Dutreix, C; Einolf, HJ; Gu, H; He, H; Ouatas, T; Rebello, S; Wang, L, 2018
)
0.48

Compound-Compound Interactions

ExcerptReferenceRelevance
" This midostaurin drug-drug interaction study assessed the dynamic response and clinical usefulness of urinary 6β-hydroxycortisol to cortisol ratio (6βCR) and plasma 4β-hydroxycholesterol (4βHC) for monitoring CYP3A4 activity in the presence or absence of rifampicin, a strong CYP3A4 inducer."( Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin.
Dutreix, C; Lorenzo, S; Wang, Y, 2014
)
0.4
" In vitro and clinical drug-drug interaction (DDI) studies indicated that midostaurin and its metabolites are substrates, reversible and time-dependent inhibitors, and inducers of CYP3A4."( Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin.
Chun, DY; Dutreix, C; Einolf, HJ; Gu, H; He, H; Ouatas, T; Rebello, S; Wang, L, 2018
)
0.48

Bioavailability

ExcerptReferenceRelevance
" After RIF comedication, relative bioavailability of CLR decreased by more than 90%."( Oral absorption of clarithromycin is nearly abolished by chronic comedication of rifampicin in foals.
Block, W; Freyer, J; Grube, M; Kroemer, HK; Lämmer, M; Lütjohann, D; Oswald, S; Peters, J; Siegmund, W; Venner, M, 2011
)
0.37
"Objective Since the majority of direct-acting antivirals (DAAs) that are used in the treatment of hepatitis C virus (HCV) infection are mainly metabolized by CYP3A4, it is hypothesized that inter-individual differences in CYP3A4 activity may be associated with the bioavailability of these agents."( Differences in the Serum 4β-hydroxycholesterol Levels of Patients with Chronic Hepatitis C Virus (HCV) Infection: A Possible Impact on the Efficacy and Safety of Interferon (IFN)-free Treatment.
Hirayama, T; Honda, A; Ikegami, T; Kohjima, M; Matsuzaki, Y; Miyazaki, T; Nakamuta, M; Yara, SI, 2018
)
0.48
" 4βOHC concentrations correlated weakly with midazolam absolute bioavailability (ρ =  - 0."( Correlations between 4β-hydroxycholesterol and hepatic and intestinal CYP3A4: protein expression, microsomal ex vivo activity, and in vivo activity in patients with a wide body weight range.
Andersson, S; Andersson, TB; Artursson, P; Åsberg, A; Christensen, H; Eide Kvitne, K; Hertel, JK; Hjelmesæth, J; Hole, K; Jansson-Löfmark, R; Johnson, LK; Karlsson, C; Krogstad, V; Molden, E; Robertsen, I; Sandbu, R; Skovlund, E; Wegler, C; Wollmann, BM, 2022
)
0.72

Dosage Studied

ExcerptRelevanceReference
" On the other hand, simulations indicated that at least 2 weeks of dosing would be needed to detect the potent inhibition of CYP3A (maximal ~40% decrease in 4βHC plasma levels)."( Does the long plasma half-life of 4beta-hydroxycholesterol impact its utility as a cytochrome P450 3A (CYP3A) metric?
Rodrigues, AD; Yang, Z, 2010
)
0.36
" In this cohort, genotypes associated with statin concentration were not differently distributed among dosing groups, implying providers had not yet optimized each patient's risk-benefit ratio."( Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care.
Choi, YH; DeGorter, MK; Dresser, GK; Hegele, RA; Iwuchukwu, O; Kim, RB; Myers, K; Schwarz, UI; Suskin, N; Tirona, RG; Wei, WQ; Wilke, RA; Zou, G, 2013
)
0.39
"4β-Hydroxycholesterol (4βOHC) is sensitive towards induction or inhibition of CYP3A4, but its potential usefulness as a dosing biomarker remains to be demonstrated."( 4β-Hydroxycholesterol level significantly correlates with steady-state serum concentration of the CYP3A4 substrate quetiapine in psychiatric patients.
Andreassen, OA; Gjestad, C; Haslemo, T; Molden, E, 2017
)
0.46
" This supports the potential usefulness of 4βOHC as a phenotype biomarker for individualized dosing of quetiapine and other drugs where systemic exposure is mainly determined by CYP3A4 metabolism."( 4β-Hydroxycholesterol level significantly correlates with steady-state serum concentration of the CYP3A4 substrate quetiapine in psychiatric patients.
Andreassen, OA; Gjestad, C; Haslemo, T; Molden, E, 2017
)
0.46
"2 observed ratio) after daily dosing of midostaurin for 4 days."( Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin.
Chun, DY; Dutreix, C; Einolf, HJ; Gu, H; He, H; Ouatas, T; Rebello, S; Wang, L, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (93)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (2.15)18.2507
2000's13 (13.98)29.6817
2010's62 (66.67)24.3611
2020's16 (17.20)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.91

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.91 (24.57)
Research Supply Index4.71 (2.92)
Research Growth Index5.62 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.91)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials16 (17.02%)5.53%
Reviews7 (7.45%)6.00%
Case Studies0 (0.00%)4.05%
Observational3 (3.19%)0.25%
Other68 (72.34%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]